We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Vertex (VRTX) Q4 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
The upcoming report from Vertex Pharmaceuticals (VRTX - Free Report) is expected to reveal quarterly earnings of $4.08 per share, indicating an increase of 8.5% compared to the year-ago period. Analysts forecast revenues of $2.5 billion, representing an increase of 8.5% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Vertex metrics that are routinely monitored and predicted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues by Product- Trikafta/Kaftrio' should arrive at $2.30 billion. The estimate points to a change of +13.6% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues by Product- Kalydeco' of $107.45 million. The estimate indicates a year-over-year change of -21%.
It is projected by analysts that the 'Revenues by Product- Orkambi' will reach $77.81 million. The estimate indicates a year-over-year change of -29.9%.
Analysts expect 'Revenues by Product- Symdeko' to come in at $25.73 million. The estimate points to a change of -24.3% from the year-ago quarter.
Shares of Vertex have experienced a change of +8.6% in the past month compared to the +3.3% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), VRTX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With Vertex (VRTX) Q4 Earnings: Wall Street's Insights on Key Metrics
The upcoming report from Vertex Pharmaceuticals (VRTX - Free Report) is expected to reveal quarterly earnings of $4.08 per share, indicating an increase of 8.5% compared to the year-ago period. Analysts forecast revenues of $2.5 billion, representing an increase of 8.5% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Vertex metrics that are routinely monitored and predicted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues by Product- Trikafta/Kaftrio' should arrive at $2.30 billion. The estimate points to a change of +13.6% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues by Product- Kalydeco' of $107.45 million. The estimate indicates a year-over-year change of -21%.
It is projected by analysts that the 'Revenues by Product- Orkambi' will reach $77.81 million. The estimate indicates a year-over-year change of -29.9%.
Analysts expect 'Revenues by Product- Symdeko' to come in at $25.73 million. The estimate points to a change of -24.3% from the year-ago quarter.
View all Key Company Metrics for Vertex here>>>
Shares of Vertex have experienced a change of +8.6% in the past month compared to the +3.3% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), VRTX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>